FSD Pharma Inc. Files 6-K Update
Ticker: QNTM · Form: 6-K · Filed: Apr 15, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, update
TL;DR
FSD Pharma dropped a 6-K update on April 15th, check the press release for deets.
AI Summary
FSD Pharma Inc. filed a Form 6-K on April 15, 2024, to report on its activities for April 2024. The filing includes a press release providing an update on the company's progress. Nathan Coyle, Chief Financial Officer, signed the report.
Why It Matters
This filing provides an update on FSD Pharma's business activities, which could impact investor understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — Form 6-K filings are typically for routine updates and do not always contain significant financial or strategic news, but can sometimes precede material announcements.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- April 15, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of April 2024.
Who signed the report on behalf of FSD Pharma Inc.?
The report was signed by Nathan Coyle, Chief Financial Officer, on behalf of FSD Pharma Inc.
What is the primary exhibit included in this filing?
The primary exhibit included is Exhibit 99.1, which is a Press Release providing an update on FSD Pharma Inc.
What is FSD Pharma Inc.'s principal executive office address?
FSD Pharma Inc.'s principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Does FSD Pharma Inc. file annual reports under Form 20-F or Form 40-F?
FSD Pharma Inc. indicates that it files annual reports under Form 20-F.
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-04-15 08:03:39
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 16KB
- fsd_ex991img6.jpg (GRAPHIC) — 7KB
- 0001654954-24-004584.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: April 15, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3